A record acquisition of HCG shares by major financial firms is drawing attention. Morgan Stanley, Nippon India Mutual Fund (MF), Motilal Oswal MF, and Plutus Wealth Management recently bought around 63 lakh HCG shares. This amounts to a 4.52% stake in HealthCare Global Enterprises (HCG).
This big deal was worth about ₹438 crore. It happened through open market trades on the National Stock Exchange (NSE). Each share was priced at ₹695.
Who Bought and Who Sold HCG Shares?
The buyers included top names like Morgan Stanley and Nippon India MF. Their large purchase shows strong interest from big investors in HCG.
The seller was CVC Capital Partners. This private equity firm is from Luxembourg. They sold these shares through their company, Aceso Company Pte Ltd, at the same ₹695 price.
After this sale, Aceso Company’s share in HCG dropped. It went from 8.76% to 4.24%. This move suggests CVC Capital Partners is changing its investments.
What’s the Impact on HCG Shares?
Such a large investment in HCG shares by big investors often signals belief in the company’s future. It means leading financial groups see value in HCG’s business, especially in specialized healthcare.
“This significant investment in HCG shares by major institutions shows strong confidence in India’s growing healthcare sector, particularly in cancer care,” says Dr. Anya Sharma, Lead Healthcare Analyst at Global Market Insights. “It confirms HCG’s leading role in the market.”
However, HCG’s shares dipped slightly after this big transaction. On Thursday, they fell 1.31% to close at ₹685.95 on the NSE. This small drop could be due to some investors selling for profit or simple market adjustments.
HCG’s Broader Investment Picture
This recent deal is part of a larger trend. Earlier this year, in February, private equity giant KKR agreed to buy up to 54% of HCG. This deal was for about USD 400 million.
Once that deal finished, KKR became the biggest shareholder in HCG. This ongoing interest from global firms highlights the attractive potential of India’s healthcare industry.
About HealthCare Global Enterprises (HCG)
HCG started in 1989. It is now one of India’s biggest cancer hospital chains. It runs 25 medical centers across 19 cities, offering vital cancer treatment.
Key Takeaways from the HCG Shares Deal
- Morgan Stanley, Nippon India MF, Motilal Oswal MF, and Plutus Wealth Management jointly acquired 63 lakh (6.3 million) HCG shares.
- This purchase represents a 4.52% stake in HealthCare Global Enterprises (HCG), valued at approximately ₹438 crore.
- Shares were bought from CVC Capital Partners (via Aceso Company Pte Ltd) at ₹695 per share.
- CVC Capital Partners’ holding in HCG reduced from 8.76% to 4.24%.
- HCG shares saw a minor 1.31% drop to ₹685.95 on the NSE the day after the transaction.
- Earlier in February, KKR acquired up to a 54% equity stake in HCG for around USD 400 million, becoming the largest shareholder.
- HCG is a leading oncology hospital chain in India, with 25 centers across 19 cities.
What Happens Next?
The continued flow of money from big investors into HCG shares points to a strong future for the company. Investors will now watch how HCG uses this confidence to expand and improve its cancer services. Market stability after these big deals will be important as HCG works to provide advanced cancer care across India.
